Journal
CANCER
Volume 125, Issue 9, Pages 1432-1440Publisher
WILEY
DOI: 10.1002/cncr.31931
Keywords
chemoimmunotherapy is right for some; chronic lymphocytic leukemia; sequencing new agents; targeted newer agents; treatment options
Categories
Funding
- Nancy Marks Family Foundation
- Helen Nash Family Foundation
- Susan Karches Family Foundation
Ask authors/readers for more resources
Within a period of just over a decade, managing chronic lymphocytic leukemia (CLL) has become more effective and yet more challenging than ever before. The important improvement in the treatment of CLL can be ascribed to the availability of many new options, mainly with the development of novel targeted therapies, such as ibrutinib, idelalisib, duvelisib and venetoclax. There are now newer tests that reliably define high-risk patients, and treatment plans can be tailored accordingly. Overall, this indeed is a new era in the treatment of patients with CLL. However, despite this progress, CLL remains an incurable disease and continues to remain challenging. In this brief review, the authors highlight the many great choices available to clinicians who manage patients with CLL and focus on the sequencing of these choices based on the available data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available